Shares of HCW Biologics (HCWB) more than doubled on Wednesday, continuing a volatile rally that has captured the attention of momentum traders. The stock surged 122% to close at $2.35, after touching an intraday high of $3.96, with approximately 188 million shares changing hands. At the closing price, the company's market capitalization stood at roughly $12.7 million.
The sharp move higher comes amid a flurry of corporate activity, including a new securities filing, ongoing discussions with Nasdaq regarding its listing status, and the release of first-quarter financial results. The broader biotech sector also posted gains, with the SPDR S&P Biotech ETF rising about 3.8% and the iShares Nasdaq Biotechnology ETF adding 2.1%.
Capital Raise and Nasdaq Challenges
HCW Biologics is seeking to raise up to $5.6 million through the sale of common stock or pre-funded warrants, according to a May 18 filing. The offering period has been extended to May 22. The company may sell up to 4.59 million shares at an assumed price of $1.22 each, or an equivalent number of pre-funded warrants, though there is no minimum offering size, meaning the final amount could be lower.
The funds are earmarked for preclinical and clinical development of HCW9302, the company's lead IL-2 fusion protein candidate, as well as research and development, marketing, working capital, and other corporate purposes. HCW9302 is designed to boost regulatory T cells, which play a key role in controlling immune responses, and is being developed as a treatment for autoimmune diseases.
Nasdaq compliance remains a significant overhang. The company received a notice on March 26 for failing to meet the $1 minimum bid price requirement. A hearing on its appeal was held on May 5, but no decision has been announced. A 1-for-40 reverse stock split executed in April 2025 makes HCW ineligible for another 180-day grace period.
Earnings and Licensing Deal
HCW reported first-quarter revenue of $6.54 million, a dramatic increase from just $5,065 in the same period a year ago. Net income attributable to common stockholders was $1.98 million, or 37 cents per share, swinging from a loss of $2.20 million, or $1.97 per share, in the year-ago quarter. The revenue surge was primarily driven by a licensing agreement with Beijing Trimmune Biotech, which closed in March. The deal included a nonrefundable upfront payment of $3.5 million in gross cash ($2.9 million after taxes) and a $3.5 million equity stake in Trimmune.
Despite the positive quarterly results, the company's long-term financial health remains uncertain. HCW noted in its filing that it has not generated revenue from commercial sales of its own immunotherapeutic products and has accumulated net losses of $102.3 million since inception. Management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
Pipeline and Competitive Landscape
CEO Hing C. Wong highlighted HCW9302 as the company's top autoimmune drug candidate, citing its "relatively high IL-2Rα affinity and sustains serum exposure." Early data from the first two dose levels of a Phase 1 trial in alopecia areata are expected in the first half of 2026. If successful, HCW9302 would compete with approved oral treatments such as Eli Lilly and Incyte's Olumiant (approved in 2022 for adults) and Pfizer's Litfulo (approved in 2023 for patients aged 12 and older). However, HCW's drug operates through a different immune-modulation pathway and is still in early-stage development.
The stock's recent rally has been fueled by short-term trading momentum rather than fundamental breakthroughs. The key catalysts ahead include completing the financing round, resolving the Nasdaq listing issue, and generating clinical data that can sustain investor interest beyond the current squeeze. Without these milestones, the stock's elevated valuation remains highly speculative.
